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Abstract
Background: Understanding of the relationship between multi-drug resistant tuberculosis and mental health is
limited. With growing prevalence of multi-drug resistant tuberculosis, addressing mental ill-health has potential to
improve treatment outcomes and well-being. In several low and middle-income contexts hospitalisation during
treatment is common. Understanding of the impact on mental ill-health are required to inform interventions for
patients with multi-drug resistant tuberculosis.
Our aim was to identify the prevalence of comorbid depression among in-patients being treated for multi-drug
resistant tuberculosis and to explore their experiences of comorbid disease and the care they received in a large
specialist chest hospital in Dhaka, Bangladesh.
Methods: We conducted a quantitative cross-sectional survey among 150 multi-drug resistant tuberculosis in-
patients (new cases = 34%, previously treated = 66%) in 2018. A psychiatrist assessed depression was assessed with
the Structured Clinical Interview for Depression (SCID DSM-IV). We used multi-level modelling to identify
associations with depression. Experience Bangladeshi researchers conducted qualitative interviews with 8 patients, 4
carers, 4 health professionals and reflective notes recorded. Qualitative data was analysed thematically.
Results: We found 33.8% (95% CI 26.7%; 41.7%) of patients were depressed. While more women were depressed
39.3% (95% CI 27.6%; 52.4%) than men 30.4% (95% CI 22%; 40.5%) this was not significant. After controlling for key
variables only having one or more co-morbidity (adjusted odds ratio [AOR] = 2.88 [95% CI 1.13; 7.33]) and being a
new rather than previously treated case (AOR = 2.33 [95% CI 1.06; 5.14]) were associated (positively) with depression.
Qualitative data highlighted the isolation and despair felt by patients who described a service predominantly
focused on providing medicines. Individual, familial, societal and health-care factors influenced resilience, nuanced
by gender, socio-economic status and home location.
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Conclusions: Patients with multi-drug resistant tuberculosis are at high risk of depression, particularly those with
co- and multi-morbidities. Screening for depression and psycho-social support should be integrated within routine
TB services and provided throughout treatment.
Keywords: Tuberculosis (TB), Multi-drug resistant (MDR-TB), Depression, Mental health, Co-morbidities, Bangladesh,
Low and middle income countries (LMIC)
Background
Mental and physical health are inextricably linked, mu-
tually reinforcing and can be considered a syndemic,
with the synergistic interaction of these two conditions
leading to an excess burden of disease [1, 2]. In this bio-
directional relationship, physical health conditions
increase the risk of poor mental health, which in turn
undermines health-seeking behaviour, diagnosis, man-
agement and outcomes [3]. Cases of multi-drug resistant
tuberculosis (MDR-TB) continue to grow globally with
160,684 cases of MDR/Rifampicin Resistant-TB detected
and notified in 2017 [4]. Globally, treatment success for
MDR-TB patients at 55% globally, remains much lower
than for drug-sensitive TB, although several high burden
countries, including Bangladesh are achieving better
treatment success rates of over 70% [4]. The need to
identify and successfully treat patients with MDR-TB is
a global priority, and yet, the limited evidence of the re-
lationship between mental health and MDR-TB under-
mines the development, testing and implementation of
interventions to realise this goal [2].
There is a growing body of evidence of the prevalence
of mental ill-health among those with MDR-TB. A re-
cent large cross-sectional study of 1279 MDR-TB pa-
tients in routine care in Pakistan found 42.8% (95% CI
40.1; 45.5) to be depressed [5]. Smaller studies have
found a range of levels of depression, including 16%
among MDR-TB patients with co-morbid HIV infection
in India [6] to 52% depressed at baseline and 13% inci-
dent cases during treatment in a review of 75 patients’
case notes following screening for psychiatric disorders
in Peru [7]. It should be noted that the strong treatment
required for MDR-TB itself can cause psychiatric side ef-
fects [8], with cycloserine particularly implicated [9] and
these are often more debilitating than other side effects
[10]. A narrative synthesis of evidence illustrates how
the stigma, loss of livelihood and discrimination leads to
catastrophic social and economic costs for patients [11].
For drug-sensitive TB, an analysis of World Health
Survey data from across 48 low and middle-income
countries (LMIC) found those with TB to have a
significantly higher odds of having a depressive epi-
sode odds ratio (OR) 3.68 (95% CI 3.01; 4.50) than
those without TB and this was significantly associated
with worse health status [12]. The bi-directional
relationship has been identified in a Korean cohort
where the risk of TB was 2.63 times higher among
those who were depressed [13].
While there is, as yet, limited evidence of the associ-
ation, it is hypothesised that poor mental health may
also trigger loss to follow up among MDR-TB patients
[2]. A meta-analysis of MDR-TB patients found the me-
dian time when loss to follow-up occurred was 7 months
(IQR = 3–11) with most of this loss occurring in the ini-
tial phase of treatment (75% in the first 11 months) [14].
The importance of using appropriate screening tools
for depression is highlighted in a recent review of com-
munity MDR-TB programmes in Bangladesh, where des-
pite only 5% of cases having documented psychiatric
symptoms in a chart review, once 60 patients were inter-
viewed, 60% reported psychiatric symptoms. As inter-
views were not conducted by a psychiatrist, it is hard to
determine the clinical significance of these symptoms,
however the study does indicate potential missed oppor-
tunities for mental health treatment [15]. The limited
but growing evidence base has raised the profile of
treatment and support for depression within National
TB programmes. A recent survey of National TB
Programme (NTP) directors from 26 high-burden TB
countries found that while only two NTPs regularly
screened for depression, 17 directors would consider in-
tegrating mental health treatment into national TB
guidelines and services [16]. Current World Health
Organisation (WHO) guidance on MDR-TB treatment
emphasises care and support for MDR-TB patients, with
psychological support specifically mentioned, however
no further details of what this should include or how
this can be delivered in different MDR-TB treatment
settings are provided [17]. Previous work on providing
psycho-social support in MDR-TB services has
highlighted feasibility challenges [18] and understanding
of the content and modalities of mental health interven-
tions for MDR-TB patients are limited. Despite an in-
creasing focus on out-patient care for MDR-TB [17], in
many high-burden countries, patients are still hospita-
lised particularly for the intensive phase of treatment. In
light of this, we wished to understand the mental health
experience of MDR-TB patients that are treated as in-
patients to inform the development of subsequent inter-
ventions to improve care and treatment.
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Methods
Our aim was to identify the prevalence of comorbid de-
pression among in-patients being treated for MDR-TB,
as well as the socio-demographic and health related cor-
relates of comorbid depression, and to explore patient
experiences of comorbid disease and the care they
received.
Design
We used a sequential mixed-methods design [19] with
an initial quantitative cross-sectional survey that in-
formed the design of qualitative interviews, reflective re-
searcher notes and the codes developed during analysis
of the qualitative data.
Setting
The study was set in the largest tertiary government run
chest hospital in Dhaka, Bangladesh treating lung dis-
eases and acting as the largest referral hospital for TB.
At the time of the study (January to July 2018), the hos-
pital had 73 beds for male TB (both MDR- and exten-
sively drug-resistant XDR-TB) patients and 46 for
female patients in separate male and female wards. Due
to limited space, the female ward often includes non-TB
patients. There was one doctor for the male and female
wards, six nurses for each ward during the day-shift and
three nurses providing the night-shift. Patients are re-
ferred from across Bangladesh normally following con-
firmation of rifampicin resistance. Following further
drug susceptibility testing at the hospital, MDR-TB pa-
tients will normally spend the first month of their treat-
ment in the hospital before being discharged following
two successive smear-negative results. They will then be
managed by TB services in the community. Those that
remain smear positive will stay in the hospital and have
a further drug susceptibility test at 3 months.
Participants
For the cross-sectional survey our participants were
adult in-patients diagnosed with MDR-TB. In close con-
sultation with hospital staff, we agreed to exclude pa-
tients who were under 18 years old, had extensive drug
resistance, were due to leave hospital within a week or
were deemed too ill by the health professionals or re-
searchers to take part in the study.
Through the qualitative interviews we aimed to under-
stand the impact of MDR-TB on patient’s lives and their
experiences of treatment in the hospital. To deepen our
understanding of these issues we purposively sampled
in-patients and cured patients, carers and health profes-
sionals. We aimed to interview both male and female pa-
tients and carers to understand gender differences in
care and experiences.
Sample size
Given the limited information on depression in this pa-
tient group we conservatively estimated the proportion
of people with depression to be 50%, and we therefore
required a sample size of 97 to estimate this prevalence
with 95% confidence intervals of at most +/− 10 percent-
age points. For the cross-sectional survey, based on in-
patient flow at the hospital and our exclusion criteria,
we estimated that approaching all in-patients over a six-
month period would meet our sample size target.
To determine the size of the qualitative sample, we
drew on principles of ‘information power’ [20]: our aim
was relatively broad, attempting to understand impacts
of MDR-TB on mental health among all patients, so in
recognition of this we included patients of different ages,
male and female; we also included care-givers to provide
perspectives on their family-member’s experiences. To
enhance information-power we drew on theory to ana-
lyse our qualitative data in the form of the socio-
ecological model [21] which identifies relationships at
individual, relationship, societal, institutional and policy
levels. Health professionals and policy makers provided
insights into the institutional and policy responses to
mental ill-health. We planned to interview four male
and four female patients of different ages. Conscious of
the poor physical and mental health of many patients,
we planned to conduct multiple interviews with the
same patient if a single long interview was not possible.
We planned to interview four carers and four health
professionals.
Cross-sectional survey measures
An initial questionnaire was conducted with recruited
patients once informed consent had been taken. This
included socio-demographic information, self-reported
co-morbidities and substance use, including mental ill-
health, any treatment taken for mental ill-health and
MDR treatment side-effects. Participants were asked to
report separately their use of tobacco, alcohol or any
other substance and to state if they had any other health
conditions. For those patients who self-reported a co-
morbidity, following patient consent and health profes-
sional approval, their patient records were checked by
the researchers and the nature of the comorbidity was
recorded. This socio-demographic questionnaire was
conducted face-to-face in Benagli by researchers who
were all employed by a Bangladesh research organisa-
tion, The ARK Foundation. Within two-weeks of this
initial assessment, a psychiatrist working as part of our
research team undertook a clinical assessment with these
patients using the depression module of the Bengali ver-
sion of the Structured Clinical Interview for DSM-IV
(SCID) [22]. The SCID is a well-used tool for psychiatric
assessments and has been used in previous studies in
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Bangladesh [23, 24]. In our study, the depression module
of the research version of this tool was used. During the
assessment, any patient identified as being severely de-
pressed or having suicidal thoughts was referred to their
hospital clinician.
Qualitative individual interviews and reflective notes
were used following the initial analysis of the cross-
sectional survey. Topics explored in the interview guides
were informed by the preliminary analysis of the ques-
tionnaire data and included: their experience of becom-
ing ill, diagnosis and care; following diagnosis with
MDR-TB, reactions and subsequent relationships with
family members, friends and wider community, experi-
ences of hospitalisation and treatment, understanding
and experiences of mental ill-health and recommenda-
tions for improving the support to patients. Interview
guides for carers covered similar topic areas in relation
to the patient they were attending and their perspectives
of their mental health and care in the hospital. Cured
patients were asked to reflect on their experiences
throughout and after completion of treatment. Provider
interviews focused on the current service provision, their
perceptions of patient mental well-being and their confi-
dence to support patients with mental ill-health.
Interviews were conducted by one senior female and
one early-career female qualitative researcher in Bengali,
employed by the ARK Foundation. Interviews were con-
ducted in the ward or adjoining outside area, as pre-
ferred by the participant. Following identification by a
health care provider, cured patients were interviewed
over the phone. Health care providers were interviewed
in their offices in the hospital or their private practices.
All interviews were audio-recorded and then as soon as
possible, transcribed into English. Both researchers spent
considerable time at the hospital building rapport with
patients, carers and staff. They recorded their observa-
tions and reflections on the physical, social and clinical
environment. Thematic qualitative analysis [25] was con-
ducted using the transcripts and the reflective notes of
the researchers. After initial familiarisation with all the
data, a coding frame was developed jointly by FF and se-
nior researcher (HE). FF coded all transcripts and re-
flective notes. HE double-coded 5 transcripts to
compare the use of codes and to further refine the cod-
ing framework.
Statistical analysis
We calculated appropriate descriptive statistics for the
socio-demographic and key health related variables to
describe our samples key relevant characteristics. As per
the SCID diagnoses we estimated the prevalence of any
level of depression and the prevalence of mild, moderate
and severe depression separately, along with the 95%
confidence intervals (CI) for each prevalence estimate
calculated via the Wilson score method [26]. We then
used a logistic regression model to estimate the associa-
tions between a range of potentially important inde-
pendent variables and the binary outcome of depressed/
not depressed as per each patients’ SCID diagnosis. We
selected the independent variables included in the model
based on those variables that were identified as likely to
be important in causing and/or influencing depression
in MDR-TB patients from the literature, and we did not
do any further model selection. We calculated adjusted
odds ratios (AOR) from our logistic regression model
coefficients along with their 95% (Wald-based) confi-
dence intervals. We excluded any patients from the
model who had any missing outcome or independent
variable data. We verified that none of the logistic re-
gression model assumptions were violated using appro-
priate methods (e.g. residual plots) [27]. We analysed all
data using R statistical software (version 3.5.1) [28, 29].
Ethics
Ethics approval was given by School of Medicine Ethics
Committee, University of Leeds (Ref no: MREC16–163)
and the National Research Ethics Committee,
Bangladesh Medical Research Council (Ref: BMRC/
NREC/2016–2019/211). Informed consent was obtained
from patients before the SCID assessment and from pa-
tients, carers, health professionals and policy makers be-
fore the qualitative interviews through reading out an
information sheet, encouraging any questions to be
asked and signing a consent sheet.
Funding
This study was conducted as part of the research
programme consortium COMDIS-HSD, which was
funded by UK Aid from the UK government. The fun-
ders had no role in study design, data collection and
analysis, decision to publish, or preparation of the
manuscript.
Results
We approached all 254 in-patients admitted between
January and July 2018. Of these 254 in-patients, 66 did
not meet our inclusion criteria as either under 18 years
old (n = 12), being discharged within a week (n = 23), di-
agnosed with XDR TB (n = 5) or too ill to be interviewed
(n = 26). Of the 188 eligible, 38 declined to be inter-
viewed and 150 completed the initial demographic ques-
tionnaire (Table 1). Of these 150, two patients left
hospital (without being discharged) and were therefore
not assessed by the psychiatrist using the SCID tool [22].
A total of 33.8% (95% CI: 26.7, 41.7%) of patients were
diagnosed as depressed (with either a mild, moderate or
severe level of depression) via the SCID tool, with most
patients diagnosed with either mild or moderate
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depression (Table 2). Our logistic regression model only
identified two variables that were statistically significantly
associated with depression in our sample: patients with
one or more co-morbidities had 2.88 (95% CI: 1.13, 7.33)
times the odds of being diagnosed with depression com-
pared to patients with no co-morbidities and patients who
were new MDR-TB cases had 2.33 (95% CI: 1.06, 5.14)
times the odds of being diagnosed with depression com-
pared to previously treated MDR-TB cases (Table 3) .
The qualitative findings provide insights into the interlink-
ing factors which are driving the challenges facing patients
with MDR-TB including those presented above in the quan-
titative analysis, but also provide further depth in under-
standing poor mental health among patients. The
Table 1 Participant characteristics
Variable Mean/% Range/n
Age (mean) 35.28 18–80
Sex Male 62% 93
Female 38% 57
Occupation Student 7% 11
Farmer 11% 16
Labourer/factory/rickshaw driver/business 64% 96
Domestic servant 8% 12
Office-based (public or private) 2% 3
Unemployed 8% 12
Marital status Single – never married 21% 32
Married 75% 113
Divorced/widowed 4% 5
Education No schooling 29% 44
Primary/Junior 39% 59
Secondary (to grade 10)/higher 31% 47
Living location Rural 46% 69
Urban 54% 81
Previously treated or new case New MDR-TB case 34% 51
Previously treated 66% 99
Substance use Any substance use 50% 75
No substance use 50% 75
Type of substance used (N = 75) Current smoker 69% 52
Drug use 9% 7
Alcohol use 1% 1
Smokeless tobacco 13% 10
Multiple substance use 8% 5
History of mental disorder Self-reported ‘yes’ to question: any history of mental disorder? 7% 10
Self-reported ‘no’ to question: any history of mental disorder? 93% 140
Co-morbidity Self-reported ‘yes’ to question: any co-morbidities? 27% 40
Self-reported ‘no’ to question: any co-morbidities? 73% 110
Type of co-morbidity (N = 40) Diabetes 50% 20
Cardiac disease 13% 5
High or low blood pressure 28% 11
Asthma 5% 2
Hernia 3% 1
Breast lump 3% 1
Kidney disease 3% 1
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characteristics of the qualitative participants are presented in
Table 4. The socio-ecological model [21] was used within
the analysis to show how these factors operate at an individ-
ual, relational, societal, institutional and policy level. These
headings are used to structure the qualitative findings below.
Individual level
Dealing with side-effects
The majority of the 8 patients interviewed described
experiencing one or more of the known side effects of
their medication including vomiting, headaches, blurred
vision, aching joints, hearing loss and imbalance. The
impact on mood was also clear:
“Like yesterday … I was planning not to take the
medicines. Why? Because, I cannot tolerate it any-
more and my mentality has been in such distress
that I wanted to skip the day’s treatment.”
(TBPM04, MDR-TB patient, male)
Health professionals were very conscious of the impact
of these side effects on patients’ mental well-being and
how this could influence their commitment to continu-
ing treatment:
“When these situations (side effects) occur during the
first three or four weeks of treatment the patients get
quite depressed. They think, ‘I am taking so many
medicines; but still my physical condition is worsen-
ing day by day’ … . There are incidents of patients
who abscond from the hospital. One of the major
challenges we face is when the patient stops taking
treatment. Sometimes the patients think that the
treatment will not work for him or her because of
their depression. What happens is that the patient
may receive the medicines everyday but not take
them and throw them away somewhere. I think, this
is one kind of expression of depression of the pa-
tient.” (DR01, Hospital doctor, male)
Continuing low mood after treatment completion
The feelings of low mood were identified by many, in-
cluding the health providers, as a continual experience,
not just linked to taking the medication. The interviews
with cured patients highlighted how, for some, even after
being successfully treated the feelings did not subside:
“The things that depressed me before are still de-
pressing me now. Such as, I couldn’t finish my study,
which is very sad for me. Secondly, this was not for a
year or two, this was five years. For these five year of
gap, I have lost many things in life. Compared to
other girls, in life I am sacrificing a lot of things.
Table 2 Prevalence of depression by severity as measured by
SCID
Outcome n/N % (95% CI)
All Patients
Any depression (mild, moderate or severe) 50/148 33.8% (26.7, 41.7)
Mild depression 27/148 18.2% (12.9, 25.2)
Moderate depression 19/148 12.8% (8.4, 19.2)
Severe depression 4/148 2.7% (1.1, 6.7)
Males only
Any depression (mild, moderate or severe) 28/92 30.4% (22, 40.5)
Mild depression 17/92 18.5% (11.9, 27.6)
Moderate depression 9/92 9.8% (5.2, 17.6)
Severe depression 2/92 2.2% (0.6, 7.6)
Females only
Any depression (mild, moderate or severe) 22/56 39.3% (27.6, 52.4)
Mild depression 10/56 17.9% (10, 29.8)
Moderate depression 10/56 17.9% (10, 29.8)
Severe depression 2/56 3.6% (1, 12.1)
N = 148 (SCID outcomes missing for 2 patients). 95% CIs calculated using
Wilson score method using R package binom [28]
Table 3 Logistic regression exploring associations between
socio-demographic and health related variables and a SCID-
based diagnosis of depression
Covariates Adjusted odds ratio (95% CI)
Age≤ 40 Ref
Age > 40 0.95 (0.38, 2.35)
Male Ref
Female 1.57 (0.57, 4.33)
Not currently/never married Ref
Married 2.89 (1, 8.37)
No education Ref
Primary/Junior 0.73 (0.29, 1.88)
Secondary/Higher 0.81 (0.29, 2.27)
Urban location Ref
Rural location 1.19 (0.55, 2.57)
Days since treatment starta 1.01 (0.99, 1.02)
Previously treated MDR-TB case Ref
New MDR-TB case 2.33 (1.06, 5.14)
Non-smoker Ref
Smoker 1 (0.37, 2.73)
No co-morbidities Ref
One or more co-morbidity 2.88 (1.13, 7.33)
Sought treatment for side effects Ref
Not sought treatment for side effects 1.38 (0.63, 3.02)
Ref reference/comparison group for dummy coded categorical variable
comparisons. N = 148 (SCID outcomes missing for 2 patients). Adjusted odds
ratios are adjusted for all variables/levels listed in the table in a logistic
regression model. 95% CIs are approximate Wald-based CIs. a Days since
treatment start and SCID diagnosis: numerical discrete variable (range = 3–138)
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These things still hurt me mentally. If I tell anyone,
they will ask me to forget everything. It is easier to
ask to forget, but difficult to do. That is why I don’t
tell anyone. I just stay by myself. I am just waiting
to see how long this depression will last.” (CPF01,
Cured MDR-TB patient, female)
Diagnosis and dealing with multiple health problems
Many patients described a complex route to TB diagno-
sis, seeking diagnosis in a range of private and public fa-
cilities. Many were unclear regarding their diagnosis and
were not specific regarding other health conditions that
they faced. However, what was clear was that these mul-
tiple diagnoses compounded the worry felt by patients.
This young, married patient describes how she became
ill following the birth of her child:
“I went to the TB-centre at the Upazila [sub-district
health centre]. There, I underwent three diagnostic
tests, but my disease was not diagnosed. After that I
went to see a doctor of [diabetes clinic] who also
treats patients here. There, I had diagnostic tests for
my whole body. The doctor said that I have liver
problem, jaundice, anaemia & some chest problems.
Then, I was in doubt. I went to a private hospital &
did an x-ray. With that x-ray & other diagnostic re-
ports, I went to BRAC [and was referred to this hos-
pital] … I am still taking the drugs and I started to
feel ok. But now, another problem has occurred, I
have a breast-tumour. Now a specimen will be taken
today for diagnosis. Right now, my mind is (laughter)
ok; but deep inside I am worried about today’s diag-
nostic test. I am already taking one sort of
Table 4 Qualitative interview participant characteristics
Care-givers
Participant ID Age Relationship with patient Education Home location Marital status Occupation Sex of patient
CGFP01 31–50 Mother No formal education Rural Married Homemaker Female
CGFP02 31–50 Mother Primary education Rural Married Homemaker Female
CGMP01 31–50 Mother No formal education Rural Married Homemaker Male
CGMP02 18–30 Wife Secondary education Rural Married Homemaker Male
Patients, cured and on treatment
Participant ID Age Sex Education Home location Marital status Occupation
CPF01 18–30 Female Secondary education Rural Widow Unemployed
CPF02 18–30 Female Higher secondary education Urban Unmarried Student
CPM01 18–30 Male Higher secondary education Urban Married Small business
CPM02 31–50 Male Higher secondary education Rural Married Small business
TBPF01 18–30 Female Secondary education Urban Married Factory worker
TBPF02 18–30 Female Primary education Rural Married Home-maker
TBPF03 18–30 Female Primary education Urban Married Home-maker
TBPF04 51 plus Female Secondary education Rural Married Home-maker
TBPM01 18–30 Male Primary education Rural Married Garment worker
TBPM02 18–30 Male No education Rural Unmarried Garment worker
TBPM03 31–50 Male Secondary education Urban Married Small-business
TBPM04 18–30 Male Unknown Rural Married Unemployed
Health Professionals
Participant ID Age Sex Education Occupation
DR01 31–50 Male MBBS Doctor
DR02 31–50 Male MBBS Doctor
N01 31–50 Female Diploma in Nursing Nurse
N02 31–50 Female Diploma in Nursing Nurse
Policy Makers
Participant ID Age Sex Education Occupation
PM01 60 Male MBBS, MPhil Government senior official/academic
PM02 55 Male MBBS, MCPS, FCPS, MD, FCCP Government senior official
PM03 45 Female MBBS, MPH Government senor official
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medication right now; but now I am having another
health problem. Who knows what will happen next?
Thinking about it, I am stressed right now.” (TBF03,
MDR-TB patient, female)
Building personal resilience
The patient interviews highlighted the different ways pa-
tients found to take their mind off their condition
through talking, singing, playing board games, and for
those who had mobile phones, listening to music and
looking at photos. Some male participants, particularly
those with higher levels of education, also talked about
writing diaries and songs:
“The truth is, whenever I feel tense, I sit down with
my paper and pen. That’s the time I feel I want to
write. I want to write in an effective way so that I
can tell each and every person in Bangladesh about
this disease. Sir I want to write in such way so that I
can express my feelings to well-known lawyers and
doctors through my song or through my words. Then
this disease can be beaten completely. Otherwise all
the young people, my children will be destroyed.”
(TBM03, MDR-TB patient, male)
For others, religion proved a powerful source of hope
and reassurance:
“My son says his prayers five times a day, he prays
to his Lord. That can give him mental peace.”
(CGMP01, Care-giver, mother of MDR-TB patient)
“I overcame my depression praying to Allah by say-
ing, ‘Allah I have lost everyone, but you are my
hope’. I had this faith in Allah.” (CPM01, Cured
MDR-TB patient, male)
The role of information and knowledge gained either
from health professionals, or more commonly from their
own experience or talking to other patients, was crucial
in helping patients to keep the impact of the side-effects
in perspective. Understanding that these were side-
effects of the medicines, rather than symptoms of their
illness helped some patients to find ways to cope:
“Towards the beginning I used to consume the medi-
cines in the morning. I noticed that I would feel bad
the entire day. I would feel demotivated to shower or
to go grocery shopping. As a result, I changed my
routine to take them in the afternoon. I’d take a nap
or rest for a bit. Then towards the evening I would
start to feel better again. It takes about four to five
hours after taking the medications for me to start
feeling better.” (TBPM01, MDR-TB patient, male)
Relationships and family
The relationships with those around them and with fam-
ily members were key to patient’s ability to cope with
the physical and mental challenges they faced. There
were considerable differences based on gender, age and
whether they had had to relocate away from their
families.
Spousal support
Interviews with male patients and their wives demon-
strated the commitment of wives to caring for their
husbands. The researchers’ observations indicate how
these differences impacted on the day-to-day welfare
of patients as well as their mental health. For ex-
ample, the male ward was frequently filled with fe-
male carers cooking, cleaning for and supporting their
patients, whereas the female ward had fewer carers
and while some had stoves for cooking few had the
energy to buy groceries and cook for themselves.
Wives commitment to their husband’s health was fre-
quently expressed:
“After he was admitted here, my husband told me
not to go near him. I didn’t pay much attention to
his instructions. Let me become infected. I told him if
I contract the disease then we’ll die together. But I
will not succumb to the idea that I cannot feed him
and take care of him just because I may be infected
as well.” (CGFP02, Care-giver, mother of MDR-TB
patient)
And as this husband explains about his wife:
“She says, “You see, today you are suffering from this
disease, but don’t be scared of it. Someday everyone
will die. I will never ever leave you. It doesn’t matter
what disease you get or how contaminating it is. I
am here with you and I will always be.” Yes, she says
so and she stays with me and this gives me positive
energy.” (TBPM03, MDR-TB patient, male)
For the wives, even when husbands were supportive, the
wives themselves encouraged them not to visit, but in-
stead to support the family at home:
“My husband supports me. I request him not to come
here; because there is no use of coming here. I am
taking the medicines and I will be cured. If he re-
mains seated beside me, will my problems be solved?
`Instead, if he works.. I have a child and there are
some expenses for my child, my husband also has
some expenses. My family cannot bear all his ex-
penses; he cannot remain seated beside me.”
(TBPF03, MDR-TB patient, female)
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All the carers of female patients that we were able to
interview were mothers of the patient. Where these
women were bread-winners for their families they strug-
gled to bear the opportunity cost of coming to care for
their daughters. When husbands abandoned wives, it fell
to the mother to provide care:
“No, he [the husband] didn't take care of her. I have
bought her here; he came to see her only one day.
Then I told him: "son you married her after seeing
we are poor, now we can't give medicines to our
daughter, give us some money so we can give her
medicines." He replied, “you always want money".
So, that's okay, we don't want his money! Now if we
can help her or not, that is our only concern.”
(CGFP01, Care-giver, mother of MDR-TB patient)
The challenges of relocating to hospital and being far
from children was frequently raised by the female pa-
tients and the break in this relationship, concerns for
how their children would be cared for in their absence,
coupled with their fear of infecting family members fur-
ther fuelled their anxiety and lowered mood:
“She says she doesn't want to stay here: “I have two
children. I want to go to the village. I don't want to
stay in Dhaka.” As I told you, she feels bad for her
children. She can't take care of her children. She
can't feed them. Her son cries. He calls her. Then she
feels sad. People strike her son. With that tension,
she feels sad.” (CGFP02, Care-giver, mother of MDR-
TB patient)
Male patients’ concerns frequently focused on the liveli-
hood of their families and feelings of guilt and worry
that they were unable to provide for them:
“Whenever I ask him, he just replies that he is wor-
ried about his family, his children and his home. He
feels bad that he contracted this disease at such an
early age. He stays sad thinking about these things.”
(CGMP02, Care-giver wife of MDR-TB patient)
Those with no family support were clearly identified as
facing particular challenges, both in terms of loneliness
and low mood, but also in eating healthily and caring for
themselves:
“For instance, I’ve noticed that some patients do not
have any family members who visit them. There are
two or three patients here who are completely alone.
That’s one thing they suffer from, loneliness. We have
family here and they don’t. They see this and they
feel this absence, they feel the loneliness. Some do
not have enough money. Here we are told that the
government will take care of everything. But except
for the rice, the rest of the food they provide - the
vegetable, meat, fish at night - are inedible. As a re-
sult, we have to spend money. For some patients they
do not receive any monetary help from their fam-
ilies.” (TBPM01, MDR-TB patient, male).
Societal Reponses
Social stigma of TB
Within the interviews, participants often struggled to
talk about the levels of stigma they experienced. Fre-
quently, at the start of the interview they would deny ex-
periencing, but by the end many shared their stories of
the negative reactions of their extended families and
wider society. This female patient explains how the
stigma from wider society can lead relatives and hus-
bands to abandon their wives:
“When I came out of my room [at home], nobody
stayed around. Everybody went inside their room.
When I put my washed clothes to dry, they moved
my clothes away. After facing these things for many
days, I said to them, “This disease affected me, so
you are doing these things to me. Just think, if you
had this disease.” After saying this, some people kept
contact with me and some people did not. When, I
was first admitted to hospital, my cousins came.
After that, nobody came. And now, no one comes to
me. … All the in-laws are (laughter) different kinds
of people. Despite of my condition my husband kept
me; so now others fight with him. They ask him why
he kept a diseased wife, they also say that he will
catch this disease someday.” (TBPF02, MDR-TB pa-
tient, female)
When asked what might be driving the level of stigma
within society, many identified infection and lack of
knowledge about TB treatment. One patient also identi-
fied the perceptions of risk behaviours of patients:
“People think they have got their disease from their
addiction to cigarettes, tobacco or other drugs. Be-
cause of this they consider us differently from their
heart.” (TBPM03, MDR-TB patient, male)
The impact of the societal view of TB, and particularly
MDR-TB were clear:
“Sometimes I feel like I will go to [the doctor] and
say, “Sir, living our life may have some significance
for our family members; but we do not have any
value in the eyes of other people.” You can only pro-
vide us with treatment … So, it is better to just to kill
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us. I said, “Please give an injection to kill me. We
are not able to stay in this society. So, kill us.”
(TBPF02, MDR-TB patient, female)
Patients had the option to leave the ward to buy food in
the stalls near to the hospital, however this brought its
own challenges:
“I don’t tell them [shop-keepers] about my condition.
But if I wear a mask then they do not let me shop or
even serve food … I feel terrible. I can’t even go out
and get a haircut or get a shave. If we go out to
nearby shops for buying groceries, then we have to ei-
ther take the mask off or they won’t allow us to get
close to them … It seems like death is a better option
than being treated like this.” (TBPM03, MDR-TB
patient, male)
Peer support
Despite the challenges of living away from home as
an in-patient, the majority of patients, male and fe-
male, shared positive experiences of the peer support
among patients on the ward. One young female pa-
tient described how she and an older patient sup-
ported each other through times of low mood and
optimism:
“But after a while, she went into depression like
me. She didn’t eat or do anything. But then, some
of my medical reports started coming good. I was
about to be released. So, then I told her:
“Grandma, we had the same situation, we both
felt depressed, that is why my reports weren’t
coming good. Then I made her understood. It
seemed like she was listening to me. She was also
staying cheerful like me, eating food. Since all of
us patients were staying together like a family, so
if one person was told, others also listened and
followed. So, their conditions improved too.”
(CPF02, cured MDR-TB patient, female)
Patients and carers described patients chatting, singing
songs and supporting each other, as explained by this
wife caring for her husband:
“Sometimes we see that one [patient] is singing and
another joins in with another song in the middle.
Then laughter breaks out among them. That helps
them to feel relaxed and happy.” (CGFP02, Care-
giver, mother of MDR-TB patient)
For those with limited support from relatives and friends
outside the hospital this was particularly important, as
one cured patient recalls:
“I had good relations with the other patients. Since I
was away from my own family, they were like family
to me.” (CPF01, Cured MDR-TB patient, female)
The close connections established between patients
meant that seeing each other’s suffering and even death,
was particularly affecting, as this cured patient
remembers:
“Many have died in front of my eyes in the ward. I
used to see many people die from the ward beside
ours. By seeing these people, I have known … I felt
more broken mentally.” (CPM02, Cured MDR-TB
patient, male)
Institutional
The interviews with doctors and nurses showed that
while they recognised that many patients would be de-
pressed throughout their stay in hospital, only a very
small minority would require treatment for depression:
“It is difficult to say this overall, but about 1% or 2%
of the patients may need treatment for depression.
The patient generally stays more or less depressed
through the entire period of the treatment starting
from when the patient was first diagnosed with
MDR-TB.” (DR01, Hospital doctor, male)
Given that 33.8% of patients were found to be depressed
on the SCID assessment tool, the assumption that only
1–2% of patients required treatment is a significant
underestimation. This is reflected in the responses from
patients, who frequently expressed the view that health
professionals were not providing any support beyond the
delivery of the MDR-TB treatment:
“If they came to us and spoke to us about our up-
dates that would help. But they seldom come for
that purpose. They visit only to administer medicine
and injection., they never visit us to ask us about our
health, whether we are feeling better or worse.”
(TBPM01, MDR-TB patient, male)
Several patients went further in their criticisms of staff,
including the cleaning staff.
“Even the doctors and nurses, even the cleaning staff
hate us very much. Today, when we were going for
sputum-specimen, the staff were also walking along
[near us]. They yelled, “Hey, why don’t you walk
through on the other side?” … “MDR patients are
barbarians, they do not understand that their dis-
ease spreads.” … The staff hate us; so why do they
come to work in this hospital? They know that there
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are patients here, and they say heartless words in
front of us; don’t they understand we feel bad?”
(TBPF02, MDR-TB patient, female)
The researchers’ observations noted the reluctance of
cleaning staff to clean the female bathrooms, feeling that
this should be done by the women themselves. The male
bathrooms were observed to be cleaner, whether this
was due to the cleaning staff or the patients’ female
care-givers, the researchers were unsure.
The lack of any means of keeping occupied was a chal-
lenge for patients and seemed to fuel their low mood.
“We have nothing here. One day I was singing, using
these bowls as musical instruments, “Bondi achi bok-
khobidhi hashpatal e”. I wrote that song, but when
the security guard heard it he came and attacked
me. He asked me “Why are you singing?” I replied,
“Sir I don’t feel good that’s why I am singing.” Then
he said “No, you are not allowed to sing here. I will
file a complaint against you and will take you from
here.” All of us stay here like this for the whole day
and night. We are like unemployed people with
nothing to do. Our mood keeps swinging with the
passing of time.” (TBPM03, MDR-TB patient, male)
Interviews with doctors and nurses, coupled with the ob-
servations of the researchers pointed to a lack of infec-
tion control procedures and staff mentioned that one
nurse was recently infected with MDR-TB.
At the time of the study, the hospital was beginning to
phase in the new nine-month treatment regimen. Policy
makers and clinicians were hopeful that this regimen
would reduce the suffering and wider impacts on pa-
tient’s livelihood and depression.
Discussion
We found 33.8% (95% CI: 26.7, 41.7) of patients with
MDR-TB were depressed, 2.7% (95% CI: 1.1, 6.7) with
severe depression, 12.8% (95% CI: 8.4, 19.2) with moder-
ate depression and 18.2% (95% CI: 12.9, 25.2) with mild
depression. The prevalence of depression among this pa-
tient group is much higher than that found in the gen-
eral Bangladesh population, estimated at 4.1% [30]. Our
findings are similar to those from a recent assessment of
MDR-TB patients in Pakistan using the PHQ-9 screen-
ing tool where 42.8% (95% CI: 40.1, 45.5) were found to
be depressed at the lower cut-off of 6, and 16.2% (95%
CI: 14.3, 18.3) at a cut-off of 10 on the PHQ-9 [5]. An
area for further exploration is the extent to which pa-
tients continue to experience depression even after suc-
cessful treatment for their TB, as indicated within our
qualitative findings, particularly in relation to the
changes in their family and social situation, occupation
and experiences of stigma and self-worth.
We also found that having one or more co-morbidities
(compared to none) and being a new MDR-TB (rather
than a previously treated case) were positively associated
with the odds of being depressed. Given that our study
was powered to identify the prevalence of depression to
a modest precision only and not to identify correlates of
depression these results are strictly exploratory, and it is
very unlikely that we have identified all important vari-
ables that are associated with depression in this patient
group. The assessment of depression in the Pakistan
MDR-TB population did not find significant associations
with new as opposed to previously treated cases or co-
morbidity [5].
The association found between mental ill-health and
multiple-morbidities has been found in other studies.
For example, a recent meta-analysis identified the risk
for depressive disorder was twice as great for people
with multimorbidity compared to those without multi-
morbidity RR: 2.13 (95% CI 1.62–2.80) [31]. The evi-
dence base on the links between mental health and TB,
particularly MDR-TB is still limited. However, few stud-
ies have explored the relationship between mental health
and TB and other morbidities. This focus on multi-
morbidities is an area where further research is needed.
The positive and possibly counter-intuitive association
between being a new vs a previously treated MDR-TB
case and likelihood of being depressed might be ex-
plained by survivorship bias. Specifically, previously
treated cases may include a larger proportion of patients
that have a more resilient mental state than is typical be-
cause they were able to survive (literally or in terms of
enduring treatment) previous TB treatment in part due
to their greater mental resilience than those who are
more prone to mental ill-health and may have been
more likely to die or be lost to the health system.
Women are at greater risk of depression in the popula-
tion [30], and specifically among those with drug-
sensitive TB, adjusted prevalence ratio (APR) 1.23 (95%
CI 1.18 to 1.27) [32] and MDR-TB, OR 1.90 (95% CI
1.52–2.38) [5]. While we found higher levels of depres-
sion among women than men, these were not significant
in our adjusted model. This may be due to our lack of
power to find associations within sub-groups. However,
the qualitative evidence points to the societal and rela-
tional challenges facing women resulting in lower levels
of social support during their treatment. Low social sup-
port has been found to be associated with depression in
drug-sensitive TB patients in Ethiopia, APR 0.89 (95%
CI 0.85 to 0.93) [32] and in a study of hospitalised
MDR-TB patients in Nigeria, patients who were sup-
ported by their own families reported fewer psychosocial
concerns compared with those who were not [33].
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Our study highlights how practices within the hospital,
such as not allowing male relatives to attend to female
patients in the female ward and the expectation that fe-
male patients should clean their own bathrooms helped
to exacerbate the limited support, both social and prac-
tical, experienced by female patients. Interviews with pa-
tients and carers illustrated how these practices are built
on wider gender norms, for example, with female pa-
tients actively encouraging spouses to maintain liveli-
hoods and care of the household rather than provide
social support to the hospitalised spouse. Previous stud-
ies have provided good evidence for models of care that
do not rely on hospitalisation of patients, finding ambu-
latory home-based care as more cost-effective [34] and
preferable to patients [35] than hospitalisation. This is
also advised within WHO guidelines [17].
Our mixed-methods approach highlights how health
professionals may underestimate the proportion of pa-
tients that are depressed with their estimates of those
needing treatment being way below the one third of pa-
tients identified as depressed. The mechanisms linking
MDR-TB and depression appear to be driven by the ex-
treme seriousness of the condition, a factor that has
been identified in other chronic conditions [36], the
wider impacts on the patients’ life and livelihood [6, 7,
11, 32] as well as the side-effects of drugs for MDR-TB
treatment [8–10]. The impact of this is seen on both pa-
tient well-being and adherence to MDR-TB treatments
[37]. The need for routine screening and provision of
treatment for depression throughout the period of treat-
ment for MDR-TB patients and integrated into routine
TB care is clear from our study in Bangladesh and simi-
lar work in other LMIC settings [5, 33, 35].
A strength of our study is the use of an assessment by
a psychiatrist using the SCID tool to identify depression.
Given the limited existing evidence of the validity of
screening tools for depression in this population groups,
psychiatrist assessment can be considered the gold
standard in assessment of depression.
The study has several limitations: firstly, the study
was conducted in only one hospital in Bangladesh,
limiting the generalisability of the findings. Secondly,
our sample size limited the assessment of which fac-
tors influence or are associated with depression. Our
qualitative interviews were conducted within the hos-
pital wards, and researchers reflected that this may
have undermined the ability of some participants to
speak openly about their experiences and conditions.
We found it harder to recruit certain participants.
This was particularly noted for younger men, who
may have been concerned about sharing ‘risk’ behav-
iours and older women, particularly those who were
illiterate and may not have felt comfortable talking
in-depth with researchers.
Conclusions
A high proportion of MDR-TB patients have depression
during their treatment. Those with multiple-morbidities
are particularly at risk of depression. Being an in-patient
with limited psycho-social support from family members
or health professionals appears to exacerbate poor men-
tal health. Improving conditions for in-patients and de-
veloping and testing interventions to support mental
well-being within routine TB care should be considered.
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